Duprey J, Izembart M, Vallée G, Goupil M
Ann Med Interne (Paris). 1986;137(7):555-8.
In order to precise their prognostic value, the anti-TSH receptor antibodies (TRAK) have been measured in 70 cases of Graves' disease treated with carbimazole. Results (expressed in percentage of inhibition of labeled TSH binding) were grouped into 7 mean values: before treatment, from 15 days to 3 months, from 3 to 12 months, 2nd, 3rd, 4th and 5th years. For all cases together, a progressive decrease was observed: 40, 37, 29, 19, 14, 10, 7 p. 100. In 16 cases with good outcome, the mean values are significantly lower than those of 29 cases with bad outcome, respectively: 33 vs 46, 29 vs 43, 17 vs 30, 12 vs 27, 11 vs 22, 3 vs 15, 1 vs 11 p. 100. The TRAK titers at whatever t time are correlated to the clinical state at t + 2 years: about 30 p. 100 relapses if the TRAK titer is less than 10 p. 100; about 80 p. 100 relapses if it is 80 p. 100. So, the anti-TSH receptor antibodies have their place among the prognostic parameters of Graves' disease treated with carbimazole.
为明确抗促甲状腺激素受体抗体(TRAK)的预后价值,对70例接受卡比马唑治疗的格雷夫斯病患者进行了该抗体检测。结果(以标记促甲状腺激素结合抑制百分比表示)分为7个均值组:治疗前、治疗后15天至3个月、3至12个月、第2年、第3年、第4年和第5年。所有病例总体呈现逐渐下降趋势:分别为40、37、29、19、14、10、7(每100个中的比例)。16例预后良好的病例,其均值显著低于29例预后不良的病例,分别为:33对46、29对43、17对30、12对27、11对22、3对15、1对11(每100个中的比例)。无论何时的TRAK滴度都与t + 2年时的临床状态相关:如果TRAK滴度小于10(每100个中的比例),复发率约为30%;如果滴度为80(每100个中的比例),复发率约为80%。因此,抗促甲状腺激素受体抗体在卡比马唑治疗的格雷夫斯病预后参数中占有一席之地。